PacBio to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
PacBio (NASDAQ:PACB) announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York. A live webcast and 30-day replay will be available on the investor website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
On the day this news was published, PACB declined 2.40%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $394.46M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Strategic partnership | Positive | -1.7% | Seed financing and collaboration with Blank Bio for RNA foundation models. |
| May 11 | Clinical study update | Positive | -3.9% | First major HiFi study on subfertility and pregnancy loss using long-read WGS. |
| May 07 | Quarterly earnings | Neutral | -14.6% | Q1 2026 results with flat revenue, improved margins, and 2026 guidance. |
| Apr 21 | Technology collaboration | Positive | -0.6% | Compatibility collaboration with Lucid Genomics for tertiary analysis workflows. |
| Apr 16 | Earnings date notice | Neutral | +3.7% | Announcement of Q1 2026 earnings call timing and access details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PACB headlines, including collaborations and scientific results, have often been followed by negative or contrary price moves, indicating a pattern of divergence between news tone and short-term reaction.
Over the last few months, PACB has reported Q1 2026 results with revenue of $37.2M, improved gross profit of $12.8M, and narrowed GAAP net loss of $8.3M, alongside guidance of $165M–$175M for 2026. It announced collaborations with Lucid Genomics and Blank Bio and highlighted a major HiFi sequencing study in subfertility. Despite generally constructive operational updates, the stock often moved lower after these events, suggesting cautious sentiment into new announcements like this conference participation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.
A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
